Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial

@article{PrietoAlhambra2013FracturePI,
  title={Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial},
  author={Daniel Prieto-Alhambra and Andrew Judge and Nigel K Arden and Cyrus Cooper and Kenneth W. Lyles and M Kassim Javaid},
  journal={Osteoporosis International},
  year={2013},
  volume={25},
  pages={77-83}
}
Patients with cognitive impairment (CI) often do not receive secondary fracture prevention. Use of zoledronic acid led to a similar reduction in re-fracture risk but the survival benefit was limited to those without CI. We tested whether the effects of zoledronic acid (Zol) on re-fracture and mortality differed in patients presenting with a hip fracture by cognitive status. We used data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial, of… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 31 references

A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients.

Journal of the American Geriatrics Society • 1975
View 7 Excerpts
Highly Influenced

Subgroup analyses.

BMJ • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…